A. D. Ho

TL;DR: In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles ofABVD following by 30 Gy ofinvolved- field radiation therapy.

TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.

TL;DR: Treatment-related mortality after reduced-intensity conditioning followed by allogeneic HSCT was low, and the procedure induced molecular remissions in patients with advanced CLL, providing evidence of a graft-versus-leukemia effect.

TL;DR: In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization.

TL;DR: In young patients with PMBCL (age-adjusted International Prognostic Index 0-1), rituximab added to six cycles of CHOP-like chemotherapy increases response rate and EFS to the same extent as other DLBCL.